SWKH Stock Analysis
SW
Neutral
Based on Eyestock quantitative analysis, SWKH`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company is headquartered in Dallas, Texas and currently employs 33 full-time employees. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables segment is a healthcare capital provider, which offers sophisticated, customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The firm's Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical-stage biopharmaceutical company offering formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. This segment utilizes the technology platform to create a portfolio of royalty income.